IBDEI0GQ ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22463,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,22464,0)
 ;;=282.60^^140^1259^110
 ;;^UTILITY(U,$J,358.3,22464,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22464,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,22464,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,22464,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,22465,0)
 ;;=282.62^^140^1259^111
 ;;^UTILITY(U,$J,358.3,22465,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22465,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,22465,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,22465,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,22466,0)
 ;;=281.1^^140^1259^121
 ;;^UTILITY(U,$J,358.3,22466,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22466,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,22466,1,5,0)
 ;;=5^Vit B12 Deficiency (Dietary)
 ;;^UTILITY(U,$J,358.3,22466,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,22467,0)
 ;;=286.7^^140^1259^53
 ;;^UTILITY(U,$J,358.3,22467,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22467,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,22467,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,22467,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,22468,0)
 ;;=289.9^^140^1259^118
 ;;^UTILITY(U,$J,358.3,22468,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22468,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,22468,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,22468,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,22469,0)
 ;;=451.9^^140^1259^119
 ;;^UTILITY(U,$J,358.3,22469,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22469,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,22469,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,22469,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,22470,0)
 ;;=446.6^^140^1259^120
 ;;^UTILITY(U,$J,358.3,22470,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22470,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,22470,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,22470,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,22471,0)
 ;;=286.4^^140^1259^123
 ;;^UTILITY(U,$J,358.3,22471,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22471,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,22471,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,22471,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,22472,0)
 ;;=204.00^^140^1259^3
 ;;^UTILITY(U,$J,358.3,22472,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22472,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,22472,1,5,0)
 ;;=5^ALL, W/O Remission
 ;;^UTILITY(U,$J,358.3,22472,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,22473,0)
 ;;=204.01^^140^1259^2
 ;;^UTILITY(U,$J,358.3,22473,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22473,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,22473,1,5,0)
 ;;=5^ALL, In Remission
 ;;^UTILITY(U,$J,358.3,22473,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,22474,0)
 ;;=204.10^^140^1259^48
 ;;^UTILITY(U,$J,358.3,22474,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22474,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,22474,1,5,0)
 ;;=5^CLL, W/O Remission
 ;;^UTILITY(U,$J,358.3,22474,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,22475,0)
 ;;=204.11^^140^1259^46
 ;;^UTILITY(U,$J,358.3,22475,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22475,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,22475,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,22475,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,22476,0)
 ;;=202.41^^140^1259^75
 ;;^UTILITY(U,$J,358.3,22476,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22476,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,22476,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,22476,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,22477,0)
 ;;=201.90^^140^1259^82
 ;;^UTILITY(U,$J,358.3,22477,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22477,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,22477,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,22477,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,22478,0)
 ;;=785.6^^140^1259^88
 ;;^UTILITY(U,$J,358.3,22478,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22478,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,22478,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,22478,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,22479,0)
 ;;=200.20^^140^1259^89
 ;;^UTILITY(U,$J,358.3,22479,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22479,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,22479,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,22479,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,22480,0)
 ;;=202.00^^140^1259^91
 ;;^UTILITY(U,$J,358.3,22480,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22480,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,22480,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,22480,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,22481,0)
 ;;=200.10^^140^1259^90
 ;;^UTILITY(U,$J,358.3,22481,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22481,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,22481,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,22481,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,22482,0)
 ;;=273.3^^140^1259^92
 ;;^UTILITY(U,$J,358.3,22482,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22482,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,22482,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,22482,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,22483,0)
 ;;=203.00^^140^1259^105
 ;;^UTILITY(U,$J,358.3,22483,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22483,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,22483,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,22483,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,22484,0)
 ;;=203.01^^140^1259^104
 ;;^UTILITY(U,$J,358.3,22484,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22484,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,22484,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,22484,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,22485,0)
 ;;=238.6^^140^1259^107
 ;;^UTILITY(U,$J,358.3,22485,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22485,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,22485,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,22485,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,22486,0)
 ;;=205.00^^140^1259^6
 ;;^UTILITY(U,$J,358.3,22486,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22486,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,22486,1,5,0)
 ;;=5^AML, W/O Remission
 ;;^UTILITY(U,$J,358.3,22486,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,22487,0)
 ;;=205.01^^140^1259^5
 ;;^UTILITY(U,$J,358.3,22487,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22487,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,22487,1,5,0)
 ;;=5^AML, In Remission
 ;;^UTILITY(U,$J,358.3,22487,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,22488,0)
 ;;=205.10^^140^1259^51
 ;;^UTILITY(U,$J,358.3,22488,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22488,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,22488,1,5,0)
 ;;=5^CML, W/O Remission
 ;;^UTILITY(U,$J,358.3,22488,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,22489,0)
 ;;=205.11^^140^1259^50
 ;;^UTILITY(U,$J,358.3,22489,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22489,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,22489,1,5,0)
 ;;=5^CML, In Remission
 ;;^UTILITY(U,$J,358.3,22489,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,22490,0)
 ;;=289.0^^140^1259^54
 ;;^UTILITY(U,$J,358.3,22490,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22490,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,22490,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,22490,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,22491,0)
 ;;=238.4^^140^1259^108
 ;;^UTILITY(U,$J,358.3,22491,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22491,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,22491,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,22491,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,22492,0)
 ;;=V58.61^^140^1259^124
 ;;^UTILITY(U,$J,358.3,22492,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22492,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,22492,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,22492,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,22493,0)
 ;;=282.49^^140^1259^116
 ;;^UTILITY(U,$J,358.3,22493,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22493,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,22493,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,22493,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,22494,0)
 ;;=289.89^^140^1259^15
 ;;^UTILITY(U,$J,358.3,22494,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22494,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,22494,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,22494,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,22495,0)
 ;;=238.79^^140^1259^87
 ;;^UTILITY(U,$J,358.3,22495,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22495,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,22495,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis Nec
 ;;^UTILITY(U,$J,358.3,22495,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,22496,0)
 ;;=287.30^^140^1259^109
 ;;^UTILITY(U,$J,358.3,22496,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22496,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,22496,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,22496,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,22497,0)
 ;;=288.09^^140^1259^7
 ;;^UTILITY(U,$J,358.3,22497,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22497,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,22497,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,22497,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,22498,0)
 ;;=284.81^^140^1259^14
 ;;^UTILITY(U,$J,358.3,22498,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22498,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,22498,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,22498,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,22499,0)
 ;;=284.89^^140^1259^13
 ;;^UTILITY(U,$J,358.3,22499,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22499,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,22499,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,22499,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,22500,0)
 ;;=284.9^^140^1259^11
 ;;^UTILITY(U,$J,358.3,22500,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22500,1,4,0)
 ;;=4^284.9
